Precision Medicine

A free virtual summit unites 20+ experts to share science-based strategies, blending traditional and lifestyle medicine to fight preventable blindness.

The diagnostics firm's stellar quarter is fueled by surging test volumes and a new non-invasive prenatal test poised to disrupt high-risk screening.

LifeMD posts record subscriber growth in Q1 driven by GLP-1 and women's health, but a planned loss from heavy marketing spend raises key questions.

Diathrive Health and AliveCor's KardiaComplete partner to offer an integrated solution for diabetes and heart disease, combating fragmented care and rising costs.

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

With a key FDA decision looming, Cristcot hires Rayna Herman to lead the commercial strategy for its first-in-class ulcerative colitis therapy, ngHCA.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Seattle-based Alpenglow Biosciences launches Summit AI, a platform moving tissue analysis beyond flat 2D slides into comprehensive 3D for drug development.

The Sugar Ray Leonard Foundation's 15th annual charity boxing night will honor Dr. Jennifer Raymond for her groundbreaking work in pediatric diabetes care.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

A new FDA-cleared system offers hope against postpartum hemorrhage, the leading cause of maternal death, earning its maker a prestigious Edison Award.

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

This Vision Health Month, learn why your eyes need more than a simple check-up and how a surgeon's specialized medical expertise is key to preventing vision loss.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

At the elite FiRe 2026 conference, Pattern Computer plans to unveil a 'hallucination-free' AI, promising a new era of scientific discovery and trust.